Psychopharmacology.
The project, poised to provide patients access to affordable medical cannabis treatment, was launched in 2019 at the Royal College of Psychiatrists in London.
The UK s national medical cannabis registry is monitored by an independent scientific body, Drug Science.
Vertically integrated CPG cannabis company
Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX:KHRNF) was the first supplier of EU-GMP high-THC dried cannabis flower to Project Twenty 21 s findings. Khiron, which has core operations in Latin America, is a founding member of Project Twenty 21.
Project Twenty 21 s Findings
The findings suggest that patients living with chronic pain, multiple sclerosis, Tourette s syndrome, epilepsy and post-traumatic stress disorder could significantly improve their quality of life by using legally prescribed cannabis.
Location
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Colombia, Peru, Germany and the United Kingdom, and is positioned to commence sales in Mexico and Brazil in 2021.
Advertisement
The Investor Summit: Khiron Life Sciences Corp.: Invitation to the Q2 Virtual Investor Summit
Toronto, Ontario (Newsfile Corp. - May 12, 2021) -
Khiron Life Sciences Corp. (TSXV: KHRN) today announced that Alvaro Torres will be attending the Q2 Virtual Investor Summit. Event Location
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Colombia, Peru, Germany and the United Kingdom, and is positioned to commence sales in Mexico and Brazil in 2021.
(1)
Khiron is a founding member of Project Twenty 21 and was the first supplier of EU-GMP high-THC dried cannabis flower to the study
The findings show that medical Cannabis dramatically improves quality of life for people with life-limiting conditions, including Chronic Pain, Multiple Sclerosis, Tourette s Syndrome and PTSD
Legal prescriptions allow patients to access medical cannabis without engaging in criminality and to avoid dependency associated with other medicines commonly prescribed for these debilitating conditions
TORONTO, May 11, 2021 /PRNewswire/ Khiron Life Sciences Corp. ( Khiron or the Company ) (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, applauds the publication today in the accredited scientific journal Psychopharmacology of the first findings arising from Project Twenty 21, UK s first and largest national medical cannabis registry that was launched on November
Khiron to Present at Canaccord Genuity s Virtual Cannabis Conference
News provided by
Share this article
Share this article
TORONTO, May 6, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ( Khiron or the Company ) (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Chairman Chris Naprawa will present live at Canaccord Genuity s 2021 Virtual Cannabis Conference on Tuesday, May 11, 2021 at 1:00 p.m. EDT (10:00 a.m. PDT).
Webcast details:
PRESENTERS: Chris Naprawa, Chairman of Khiron Board of Directors
REGISTER LINK:
Recently Announced Khiron Highlights
With the start of medical cannabis insurance coverage in Colombia in December 2020, the Company filled approximately 135% more prescriptions in Q1 2021 than in all of 2020. Additionally, in Q1 2021, 60% of medical cannabis prescriptions filled in Colombia were fully covered by insurance.